A citation-based method for searching scientific literature

Bart Keymeulen, Evy Vandemeulebroucke, Anette G Ziegler, Chantal Mathieu, Leonard Kaufman, Geoff Hale, Frans Gorus, Michel Goldman, Markus Walter, Sophie Candon, Liliane Schandene, Laurent Crenier, Christophe De Block, Jean-Marie Seigneurin, Pieter De Pauw, Denis Pierard, Ilse Weets, Peppy Rebello, Pru Bird, Eleanor Berrie, Mark Frewin, Herman Waldmann, Jean-François Bach, Daniel Pipeleers, Lucienne Chatenoud. N Engl J Med 2005
Times Cited: 784







List of co-cited articles
1206 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus.
Kevan C Herold, William Hagopian, Julie A Auger, Ena Poumian-Ruiz, Lesley Taylor, David Donaldson, Stephen E Gitelman, David M Harlan, Danlin Xu, Robert A Zivin,[...]. N Engl J Med 2002
835
50

Rituximab, B-lymphocyte depletion, and preservation of beta-cell function.
Mark D Pescovitz, Carla J Greenbaum, Heidi Krause-Steinrauf, Dorothy J Becker, Stephen E Gitelman, Robin Goland, Peter A Gottlieb, Jennifer B Marks, Paula F McGee, Antoinette M Moran,[...]. N Engl J Med 2009
628
39

Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomised, placebo-controlled trial.
Nicole Sherry, William Hagopian, Johnny Ludvigsson, Sunil M Jain, Jack Wahlen, Robert J Ferry, Bruce Bode, Stephen Aronoff, Christopher Holland, David Carlin,[...]. Lancet 2011
290
33

Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial.
Tihamer Orban, Brian Bundy, Dorothy J Becker, Linda A DiMeglio, Stephen E Gitelman, Robin Goland, Peter A Gottlieb, Carla J Greenbaum, Jennifer B Marks, Roshanak Monzavi,[...]. Lancet 2011
347
29

Teplizumab preserves C-peptide in recent-onset type 1 diabetes: two-year results from the randomized, placebo-controlled Protégé trial.
William Hagopian, Robert J Ferry, Nicole Sherry, David Carlin, Ezio Bonvini, Syd Johnson, Kathryn E Stein, Scott Koenig, Anastasia G Daifotis, Kevan C Herold,[...]. Diabetes 2013
115
28

Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: metabolic and immunologic features at baseline identify a subgroup of responders.
Kevan C Herold, Stephen E Gitelman, Mario R Ehlers, Peter A Gottlieb, Carla J Greenbaum, William Hagopian, Karen D Boyle, Lynette Keyes-Elstein, Sudeepta Aggarwal, Deborah Phippard,[...]. Diabetes 2013
183
26

Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass.
B Keymeulen, M Walter, C Mathieu, L Kaufman, F Gorus, R Hilbrands, E Vandemeulebroucke, U Van de Velde, L Crenier, C De Block,[...]. Diabetologia 2010
211
23

Staging presymptomatic type 1 diabetes: a scientific statement of JDRF, the Endocrine Society, and the American Diabetes Association.
Richard A Insel, Jessica L Dunne, Mark A Atkinson, Jane L Chiang, Dana Dabelea, Peter A Gottlieb, Carla J Greenbaum, Kevan C Herold, Jeffrey P Krischer, Åke Lernmark,[...]. Diabetes Care 2015
321
22

Alefacept provides sustained clinical and immunological effects in new-onset type 1 diabetes patients.
Mark R Rigby, Kristina M Harris, Ashley Pinckney, Linda A DiMeglio, Marc S Rendell, Eric I Felner, Jean M Dostou, Stephen E Gitelman, Kurt J Griffin, Eva Tsalikian,[...]. J Clin Invest 2015
137
22

Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trial.
Diane K Wherrett, Brian Bundy, Dorothy J Becker, Linda A DiMeglio, Stephen E Gitelman, Robin Goland, Peter A Gottlieb, Carla J Greenbaum, Kevan C Herold, Jennifer B Marks,[...]. Lancet 2011
226
21

An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes.
Kevan C Herold, Brian N Bundy, S Alice Long, Jeffrey A Bluestone, Linda A DiMeglio, Matthew J Dufort, Stephen E Gitelman, Peter A Gottlieb, Jeffrey P Krischer, Peter S Linsley,[...]. N Engl J Med 2019
182
21

A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes.
Kevan C Herold, Stephen E Gitelman, Umesh Masharani, William Hagopian, Brygida Bisikirska, David Donaldson, Kristina Rother, Beverly Diamond, David M Harlan, Jeffrey A Bluestone. Diabetes 2005
456
20

Type 1 diabetes immunotherapy using polyclonal regulatory T cells.
Jeffrey A Bluestone, Jane H Buckner, Mark Fitch, Stephen E Gitelman, Shipra Gupta, Marc K Hellerstein, Kevan C Herold, Angela Lares, Michael R Lee, Kelvin Li,[...]. Sci Transl Med 2015
471
20


Low-dose otelixizumab anti-CD3 monoclonal antibody DEFEND-1 study: results of the randomized phase III study in recent-onset human type 1 diabetes.
Ronnie Aronson, Peter A Gottlieb, Jens S Christiansen, Thomas W Donner, Emanuele Bosi, Bruce W Bode, Paolo Pozzilli. Diabetes Care 2014
67
25

Costimulation modulation with abatacept in patients with recent-onset type 1 diabetes: follow-up 1 year after cessation of treatment.
Tihamer Orban, Brian Bundy, Dorothy J Becker, Linda A Dimeglio, Stephen E Gitelman, Robin Goland, Peter A Gottlieb, Carla J Greenbaum, Jennifer B Marks, Roshanak Monzavi,[...]. Diabetes Care 2014
108
17

Effects of oral insulin in relatives of patients with type 1 diabetes: The Diabetes Prevention Trial--Type 1.
Jay S Skyler, Jeffrey P Krischer, Joseph Wolfsdorf, Catherine Cowie, Jerry P Palmer, Carla Greenbaum, David Cuthbertson, Lisa E Rafkin-Mervis, H Peter Chase, Ellen Leschek. Diabetes Care 2005
384
17

Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice.
L Chatenoud, E Thervet, J Primo, J F Bach. Proc Natl Acad Sci U S A 1994
497
17

Seroconversion to multiple islet autoantibodies and risk of progression to diabetes in children.
Anette G Ziegler, Marian Rewers, Olli Simell, Tuula Simell, Johanna Lempainen, Andrea Steck, Christiane Winkler, Jorma Ilonen, Riitta Veijola, Mikael Knip,[...]. JAMA 2013
523
17


Partial exhaustion of CD8 T cells and clinical response to teplizumab in new-onset type 1 diabetes.
S Alice Long, Jerill Thorpe, Hannah A DeBerg, Vivian Gersuk, James Eddy, Kristina M Harris, Mario Ehlers, Kevan C Herold, Gerald T Nepom, Peter S Linsley. Sci Immunol 2016
72
22

Beta-cell function and the development of diabetes-related complications in the diabetes control and complications trial.
Michael W Steffes, Shalamar Sibley, Melissa Jackson, William Thomas. Diabetes Care 2003
449
15

Nasal insulin to prevent type 1 diabetes in children with HLA genotypes and autoantibodies conferring increased risk of disease: a double-blind, randomised controlled trial.
Kirsti Näntö-Salonen, Antti Kupila, Satu Simell, Heli Siljander, Tiina Salonsaari, Anne Hekkala, Sari Korhonen, Risto Erkkola, Jukka I Sipilä, Lotta Haavisto,[...]. Lancet 2008
241
15

B-lymphocyte depletion with rituximab and β-cell function: two-year results.
Mark D Pescovitz, Carla J Greenbaum, Brian Bundy, Dorothy J Becker, Stephen E Gitelman, Robin Goland, Peter A Gottlieb, Jennifer B Marks, Antoinette Moran, Philip Raskin,[...]. Diabetes Care 2014
114
15

GAD65 antigen therapy in recently diagnosed type 1 diabetes mellitus.
Johnny Ludvigsson, David Krisky, Rosaura Casas, Tadej Battelino, Luis Castaño, James Greening, Olga Kordonouri, Timo Otonkoski, Paolo Pozzilli, Jean-Jacques Robert,[...]. N Engl J Med 2012
188
14

TGF-beta-dependent mechanisms mediate restoration of self-tolerance induced by antibodies to CD3 in overt autoimmune diabetes.
Mériam Belghith, Jeffrey A Bluestone, Samia Barriot, Jérôme Mégret, Jean-François Bach, Lucienne Chatenoud. Nat Med 2003
477
14

Effect of Oral Insulin on Prevention of Diabetes in Relatives of Patients With Type 1 Diabetes: A Randomized Clinical Trial.
Jeffrey P Krischer, Desmond A Schatz, Brian Bundy, Jay S Skyler, Carla J Greenbaum. JAMA 2017
65
21

Anti-thymocyte globulin/G-CSF treatment preserves β cell function in patients with established type 1 diabetes.
Michael J Haller, Stephen E Gitelman, Peter A Gottlieb, Aaron W Michels, Stephen M Rosenthal, Jonathan J Shuster, Baiming Zou, Todd M Brusko, Maigan A Hulme, Clive H Wasserfall,[...]. J Clin Invest 2015
93
13

Remodeling T cell compartments during anti-CD3 immunotherapy of type 1 diabetes.
S Alice Long, Jerill Thorpe, Kevan C Herold, Mario Ehlers, Srinath Sanda, Noha Lim, Peter S Linsley, Gerald T Nepom, Kristina M Harris. Cell Immunol 2017
27
48

Genetics, pathogenesis and clinical interventions in type 1 diabetes.
Jeffrey A Bluestone, Kevan Herold, George Eisenbarth. Nature 2010
658
13



Demonstration of islet-autoreactive CD8 T cells in insulitic lesions from recent onset and long-term type 1 diabetes patients.
Ken T Coppieters, Francesco Dotta, Natalie Amirian, Peter D Campbell, Thomas W H Kay, Mark A Atkinson, Bart O Roep, Matthias G von Herrath. J Exp Med 2012
394
12

Etanercept treatment in children with new-onset type 1 diabetes: pilot randomized, placebo-controlled, double-blind study.
Lucy Mastrandrea, Jihnhee Yu, Torsten Behrens, John Buchlis, Christine Albini, Shannon Fourtner, Teresa Quattrin. Diabetes Care 2009
142
11

Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials.
Antoinette Moran, Brian Bundy, Dorothy J Becker, Linda A DiMeglio, Stephen E Gitelman, Robin Goland, Carla J Greenbaum, Kevan C Herold, Jennifer B Marks, Philip Raskin,[...]. Lancet 2013
206
11

Type 1 diabetes.
Mark A Atkinson, George S Eisenbarth, Aaron W Michels. Lancet 2014
987
11

Changes in T-cell subsets identify responders to FcR-nonbinding anti-CD3 mAb (teplizumab) in patients with type 1 diabetes.
James E Tooley, Nalini Vudattu, Jinmyung Choi, Chris Cotsapas, Lesley Devine, Khadir Raddassi, Mario R Ehlers, James G McNamara, Kristina M Harris, Sai Kanaparthi,[...]. Eur J Immunol 2016
35
31

GAD treatment and insulin secretion in recent-onset type 1 diabetes.
Johnny Ludvigsson, Maria Faresjö, Maria Hjorth, Stina Axelsson, Mikael Chéramy, Mikael Pihl, Outi Vaarala, Gun Forsander, Sten Ivarsson, Calle Johansson,[...]. N Engl J Med 2008
332
11

Rapamycin/IL-2 combination therapy in patients with type 1 diabetes augments Tregs yet transiently impairs β-cell function.
S Alice Long, Mary Rieck, Srinath Sanda, Jennifer B Bollyky, Peter L Samuels, Robin Goland, Andrew Ahmann, Alex Rabinovitch, Sudeepta Aggarwal, Deborah Phippard,[...]. Diabetes 2012
209
11

Fall in C-peptide during first 2 years from diagnosis: evidence of at least two distinct phases from composite Type 1 Diabetes TrialNet data.
Carla J Greenbaum, Craig A Beam, David Boulware, Stephen E Gitelman, Peter A Gottlieb, Kevan C Herold, John M Lachin, Paula McGee, Jerry P Palmer, Mark D Pescovitz,[...]. Diabetes 2012
190
11

Targeting of memory T cells with alefacept in new-onset type 1 diabetes (T1DAL study): 12 month results of a randomised, double-blind, placebo-controlled phase 2 trial.
Mark R Rigby, Linda A DiMeglio, Marc S Rendell, Eric I Felner, Jean M Dostou, Stephen E Gitelman, Chetanbabu M Patel, Kurt J Griffin, Eva Tsalikian, Peter A Gottlieb,[...]. Lancet Diabetes Endocrinol 2013
105
11

Metabolic and immune effects of immunotherapy with proinsulin peptide in human new-onset type 1 diabetes.
Mohammad Alhadj Ali, Yuk-Fun Liu, Sefina Arif, Danijela Tatovic, Hina Shariff, Vivienne B Gibson, Norkhairin Yusuf, Roman Baptista, Martin Eichmann, Nedyalko Petrov,[...]. Sci Transl Med 2017
88
12

Low-dose interleukin 2 in patients with type 1 diabetes: a phase 1/2 randomised, double-blind, placebo-controlled trial.
Agnès Hartemann, Gilbert Bensimon, Christine A Payan, Sophie Jacqueminet, Olivier Bourron, Nathalie Nicolas, Michèle Fonfrede, Michelle Rosenzwajg, Claude Bernard, David Klatzmann. Lancet Diabetes Endocrinol 2013
231
10


Differential Insulitic Profiles Determine the Extent of β-Cell Destruction and the Age at Onset of Type 1 Diabetes.
Pia Leete, Abby Willcox, Lars Krogvold, Knut Dahl-Jørgensen, Alan K Foulis, Sarah J Richardson, Noel G Morgan. Diabetes 2016
132
10

Antithymocyte globulin therapy for patients with recent-onset type 1 diabetes: 2 year results of a randomised trial.
Stephen E Gitelman, Peter A Gottlieb, Eric I Felner, Steven M Willi, Lynda K Fisher, Antoinette Moran, Michael Gottschalk, Wayne V Moore, Ashley Pinckney, Lynette Keyes-Elstein,[...]. Diabetologia 2016
41
24

Residual insulin production and pancreatic ß-cell turnover after 50 years of diabetes: Joslin Medalist Study.
Hillary A Keenan, Jennifer K Sun, Jared Levine, Alessandro Doria, Lloyd P Aiello, George Eisenbarth, Susan Bonner-Weir, George L King. Diabetes 2010
311
10

Insulitis and β-Cell Mass in the Natural History of Type 1 Diabetes.
Martha Campbell-Thompson, Ann Fu, John S Kaddis, Clive Wasserfall, Desmond A Schatz, Alberto Pugliese, Mark A Atkinson. Diabetes 2016
177
10

Treatment of patients with new onset Type 1 diabetes with a single course of anti-CD3 mAb Teplizumab preserves insulin production for up to 5 years.
Kevan C Herold, Stephen Gitelman, Carla Greenbaum, Jennifer Puck, William Hagopian, Peter Gottlieb, Peter Sayre, Peter Bianchine, Emelita Wong, Vicki Seyfert-Margolis,[...]. Clin Immunol 2009
133
9

Genome-wide association study and meta-analysis find that over 40 loci affect risk of type 1 diabetes.
Jeffrey C Barrett, David G Clayton, Patrick Concannon, Beena Akolkar, Jason D Cooper, Henry A Erlich, Cécile Julier, Grant Morahan, Jørn Nerup, Concepcion Nierras,[...]. Nat Genet 2009
9


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.